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Abstract
Purpose This study was conducted to examine the outcomes
in patients with prior stroke/transient ischemic attack (CVA/
TIA) after atrial fibrillation (AF) ablation and the feasibility of
discontinuing oral anticoagulation (OAC).
Methods This study examined long-term outcomes following
AF ablations in 108 patients with a history of prior thrombo-
embolic CVA/TIA. Because of risks of OAC, we frequently
discontinue OAC in these patients after successful ablation.
These patients understand the risks/benefits of discontinuing
OAC and remain on OAC for a longer time following suc-
cessful AF ablation, compared to our patients without prior
CVA/TIA.
Results Patient age was 66.2±9.0 years with an average
CHADS2 score=3.0±0.9 and CHA2DS2-VASc score=4.1±
1.4. Following 1.24 ablations, 71 (65.7 %) patients were AF
free 2.8±1.6 (median 2.3)years after their last ablation. OAC
was discontinued in 55/71 (77.5 %) patients an average of
7.3 months following the final ablation. These 55 patients had
2.2±1.3 (median 1.8)years of follow-up off of OAC. Kaplan–
Meier analysis suggests little AF recurrence >1 year following
initial or final ablations, suggesting that 1 year post successful
ablation may be the appropriate time to consider discontinuing
OAC. Thirty-seven patients had AF postablation, and 32/37
(86.5 %) remained on OAC. One patient with a mechanical
valve had a stroke despite OAC. Bleeding occurred in 8.3 %
of patients on OAC and 0 % of patients off OAC (P=0.027).
Conclusions Patients with prior CVA/TIAs, who undergo
successful AF ablation, have a low incidence of subsequent
thromboembolic events. Most patients who appear AF free
postablation may be able to discontinue OAC after successful
ablation with a low thromboembolic risk and with a reduced
bleeding risk.
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ablation . Anticoagulation after AF ablation
1 Introduction
Atrial fibrillation (AF) is a major cause of thromboembolic
events including strokes (CVA) and transient ischemic attacks
(TIAs) [1]. Radiofrequency ablation has the potential to elim-
inate AF in the majority of patients. Based on little objective
data, current guidelines [1–3] recommend continuation of oral
anticoagulation (OAC) with warfarin or newer anticoagulants
after AF ablation in patients at high risk for thromboembolic
events prior to ablation, even if the ablation appears to have
eliminated AF. Despite the fact that AF ablation appears to
reduce the risk for subsequent thromboembolic events in AF
patients back to the level of stroke risk in patients with no
history of AF across all CHADS2 profiles and ages [4], very
few studies [5, 6] have described the outcome in high-risk
patients with apparently successful AF ablation who have had
OAC therapy discontinued. In the present study, we examined
the long-term outcome in patients with a prior history of
stroke/transient ischemic attack (CVA/TIA) who have under-
gone AF ablation. We especially emphasized the outcome in
those patients with a successful AF ablation who have had
OAC therapy discontinued.
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2 Methods
The subjects were 108 consecutive symptomatic patients un-
dergoing AF ablation at Sequoia Hospital, Redwood City,
California, from October 10, 2003, to December 31, 2011,
who had a prior history of thromboembolic CVA/TIA. They
were drawn from a total cohort of 1,411 patients undergoing
1,906 AF ablations.Minimum follow-up was 1 year following
final ablation. All signed written informed consent. Data
collection was prospective and approved by the hospital
IRB. AF type was categorized as paroxysmal (lasting <1 week
or requiring pharmacological or electrical cardioversion in
<48 h), persistent (lasting >1 week and <1 year or requiring
pharmacological or electrical cardioversion between 48 h and
1 week), and longstanding persistent (lasting >1 year) [1].
2.1 Ablation protocol
Our ablation protocol [7] and anticoagulation strategy [8] have
been previously published. Antiarrhythmic drugs (AADs)
were stopped ≥5 half-lives and amiodarone >3 months before
ablation. General anesthesia and right groin venous access
were used in most ablations. A 7F duodecapolar catheter (St.
Jude (St. Paul, MN) Livewire™) was placed around the
tricuspid valve annulus with the distal poles in the coronary
sinus. A 9F Boston Scientific (Natick, MA) Ultra Ice™ cath-
eter guided the transseptal puncture, done using a 71-cm St.
Jude BRK™ or Baylis (Montreal, QC) NRG™ needle [9].
Patients had a femoral or radial arterial line. The St. Jude
NavX™ mapping system was used in all cases. Prior to
January, 2006, we used a closed-tip catheter (Boston Scientific
Blazer II™ or Webster (Diamond Bar, CA) Celsius™ 8 mm)
and, thereafter, an open irrigated-tip catheter (Webster
Thermocool™ 3.5 mm, St. Jude Cool Path™, or Safire-
Blu™ 4.0 mm). Most irrigated-tip catheter ablations were
done using 50 W and the technique of “perpetual motion”
where the catheter is moved back and forth across a small area
and not left at single sites for extended times [10]. All patients
underwent circumferential atrial ablation around all
pulmonary veins (PVs) and a left atrium (LA) roof-line abla-
tion. Only patients with right or LA isthmus flutter underwent
a cavotricuspid or mitral isthmus linear ablation. Many pa-
tients had low posterior LA lines, and those with persistent AF
and LA CFAE had them ablated. Some patients with
longstanding persistent AF underwent ablation in the coronary
sinus (at 30–35W) and/or right atrium and superior vena cava
isolation. After wide area ablation around all veins, a circum-
ferential mapping catheter (7F Webster Lasso™ or St. Jude
Reflexion Spiral™) was used to isolate all PVs defined as
complete local electrical silence indicating entrance block.
After May 2010, all patients underwent pacing from the PVs
to document exit block. NavX™ activation and entrainment
mapping were used to ablate flutters and tachycardias.
Isoproterenol was given, and non-PV triggers were mapped
and ablated.
2.2 Anticoagulation
Patients receiving warfarin continued it until 5 days
preprocedure. Three days preprocedure, they began
enoxaparin 1 mg/kg every 12 h with the last dose 24 h
preablation. Patients on dabigatran had it discontinued 36 h
preablation [10] or earlier based on renal function. Most
patients underwent transesophageal echocardiogram. When
the transseptal sheath entered the LA, we gave a heparin bolus
followed by a 1,000-U/h infusion through the transseptal
sheath adjusted by the activated clotting time (ACT). The
initial target ACT was 300–350 s, reduced to 225 after the
irrigated-tip catheter was introduced [8]. Postablation, we
used enoxaparin 0.5 mg/kg q12h starting immediately
postablation until warfarin (continued ≥3 months) achieved
an international normalized ratio (INR) of 2.0–3.0. After
November 2010, patients receiving dabigatran following ab-
lation [11] received two doses of enoxaparin 0.5 mg/kg—the
first immediately after the procedure and a second dose 12 h
later before resuming dabigatran the morning after the proce-
dure approximately 10 h after the second dose of enoxaparin.
2.3 Data collection and analysis
For each patient, we recorded age, gender, AF duration and
type, number of antiarrhythmic drugs failed, CHADS2 and
CHA2DS2-VASC scores, body mass index (BMI), LA size,
prior cardioversions, and comorbidities including hyperten-
sion, diabetes, and coronary artery disease.
2.4 Follow-up
Many patients were treated with antiarrhythmic drugs during
the 3-month blanking period postablation. Patients transmitted
daily electrocardiogram (ECG) strips for 1–3 months
postablation and were seen at 3 months when an echocardio-
gram and ambulatory ECG monitoring for 7–21 days were
performed. Initial ablation failures, defined as recurrent AF,
atrial tachycardia, or atrial flutter lasting >30 s off of drugs
≥3 months postprocedure were left on OAC, and the patient
was encouraged to undergo a repeat ablation. Patients were
seen or contacted frequently by phone from 3 to 12 months
and returned for a 1-year follow-up with echocardiogram and
24-h ECG. Thereafter, every 6–12 months, patients were seen
directly or contacted via telephone by research nurses or the
attending physician, and arrhythmia records were obtained
from hospitals and referring physicians. Patients with a prior
CVA/TIA who were AF free postablation were continued on
OAC longer than our usual time of 3 months in patients
without a prior CVA/TIA. Prior to discontinuing OAC,
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CVA/TIA patients underwent a 7–21-day continuous record-
ing with an ambulatory ECGmonitor to document the absence
of silent or asymptomatic AF. Pacemaker AF data were uti-
lized when available. Patients were taught to check their pulse
daily and to notify us immediately if they had any irregular
pulse or symptoms suggesting a possible return of AF, and
ECG recorders were reissued to them.
2.5 Long-term complications
During the postprocedural follow-up, we evaluated all patients
for CVAs/TIAs or systemic thromboembolism. We also eval-
uated each patient for bleeding complications. Since all pa-
tients initially started on OAC, we classified bleeding compli-
cations as to whether they occurred while a patient was on
OAC or off OAC.
2.6 Statistical analysis
Statistical analysis was done using XLSTAT 2012 (Paris,
France). Continuous data were described as mean ± standard
deviation and categorical data as counts and percentages.
Student's t test, chi-squared test, and Fisher's exact test were
used to compare differences between clinical variables, the
number of patients on OAC in the groups rendered AF free by
ablation and those not rendered AF free, and the number of
bleeding episodes among patients on OAC versus off OAC.
Kaplan–Meier curves were generated for AF-free survival in
years for the entire group by AF type for the initial ablation
and for final outcome. All tests were two sided, and P <0.05
was considered statistically significant.
3 Results
3.1 Patient population and ablation outcome
The 108 patients with a history of CVA/TIA represented 7.9%
of our patients undergoing AF ablation. Table 1 shows the
clinical characteristics of these patients. The average age was
66.2±9.0 years. LA size was 4.36±0.65 cm. The average
CHADS2 score was 3.0±0.9, and CHADSVASC score was
4.1±1.4. Forty (37.0 %) patients had paroxysmal AF, 50
(46.3 %) had persistent AF, and 18 (16.7 %) had longstanding
persistent AF. Eighty-six patients underwent one ablation, 18
underwent two, and 4 underwent three ablations for an aver-
age of 1.24 ablations/patient. Seventy-one patients (65.7 %)
were rendered AF free after one or more ablations, an average
of 2.8±1.6 (median 2.3)years following their final ablation,
and 37 (34.3 %) remained with AF. The number of prior
cardioversions was the only statistically significant difference
in the clinical characteristics between the patients who were
rendered AF free by their ablation and those who were not.
Table 2 shows the distribution of CHADS2 and CHA2DS2-
VASC scores in the cohort of 108 patients.
3.2 Long-term anticoagulation
Among the 71 patients rendered AF free by ablation, 41 were
on aspirin and 14 were on no anticoagulation. Thus, 55 of 71
patients (77.5 %) were off of OACs. Eight patients remained
on warfarin, seven on dabigatran, and one on rivaroxaban.
The reasons for continuation of OAC among these 16 patients
were patient choice in three patients, physician choice in ten
Table 1 Clinical characteristics
for all patients with prior CVA/
TIA, for the subgroups rendered
AF free, and for those with recur-
rent AF postablation
a Statistically significant







Left atrial size (cm) 4.36±0.65 4.32±0.68 4.49±0.65 0.199
Age (years) 66.2±9.0 66.1±8.6 66.4±9.1 0.884
Duration of AF (years) 7.8±7.1 7.0±6.3 9.0±8.2 0.164
Repeat ablations 20.4 % 20.5 % 21.1 % 1.000
% Male 62.9 % 64.8 % 59.5 % 0.533
Prior cardioversions 55.5 % 47.9 % 70.3 % 0.041a
Number of antiarrhythmic
drugs failed
1.45±1.16 1.38±1.22 1.58±1.00 0.386
Average CHADS2 score 3.0±0.9 3.1±0.9 3.0±1.0 0.772
Average CHA2DS2-VASC score 4.1±1.4 4.1±1.3 4.0±1.6 0.886
Hypertension 62.9 % 69.0 % 51.3 % 0.093
Diabetes 14.5 % 15.1 % 13.5 % 1.000
Coronary artery disease 26.8 % 22.5 % 35.1 % 0.176
Body mass index 28.6±5.0 28.4±4.7 29.0±5.7 0.539
Paroxysmal AF 37.0 % 43.6 % 24.2 % 0.060
Persistent AF 46.3 % 43.6 % 53.8 % 0.310
Longstanding AF 16.7 % 12.7 % 22.0 % 0.173
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patients, patient and physician choice in two patients, and
dilated cardiomyopathy in one patient. There were no clinical
differences between those 55 patients stopping OAC and the
16 continuing onOACwith regard to age (66.3±8.5 vs. 66.0±
9.2, P=0.90), CHADS2 score (3.2±0.9 vs. 3.1±0.7, P=1.0),
or LA size (4.2±0.6 vs. 4.3±0.7, P=0.70). Among the 37
patients with AF persisting following ablation, 3 were on
aspirin, 2 were on no anticoagulants, 20 were on warfarin,
11 were on dabigatran, and 1 was on rivaroxaban. Of the five
patients failing ablation and off of OAC, three refused
anticoagulation but were completely AF free on an antiar-
rhythmic drug, and two were off OAC because of recurrent
bleeding. The difference in numbers of patients off of OAC in
the AF-free (55/71) versus AF recurrent (5/37) patients was
statistically significant (P <0.0005).
3.3 Timing of anticoagulant discontinuation
The average duration of follow-up after the patient's last AF
ablation for the entire cohort of 108 patients was 2.8±1.6 years
(median 2.3 years). All patients were followed for a minimum
of 1 year following their final ablation. Among the 55 patients
who appeared AF free following ablation and in whom OAC
was discontinued, OAC was discontinued an average of
7.3 months following their final ablation. The duration of
follow-up after discontinuation of OAC averaged 2.2±1.3
(median=1.8)years.
3.4 Time of AF recurrence following initial and final ablation
Figure 1 shows the Kaplan–Meier AF-free curve for the entire
cohort following initial and final ablations by AF type. It can
be seen that for both the initial ablation and the final outcome,
the more persistent the AF, the worse the outcome. The curve
becomes nearly flat at 1 year after the initial ablation. Of the
58 patients who remained AF free for more than 1 year after
initial ablation, there were only three (5.2 %) having a later
recurrence of AF. After the final ablation, the curves also
become nearly flat after approximately 1 year of follow-up.
Following the final ablation, 72 patients were AF free at 1 year
and only one (1.4%) had a relapse after 1 year, and that patient
relapsed at 1.1 years. Our data suggests one should wait for
1 year after an initial or repeat ablations before discontinuing
OAC in patients with a prior CVA/TIAwho appear to have a
successful ablation.
3.5 Clinical outcomes
There were no CVA/TIA events or systemic thromboembolic
events in any of the 71 patients who were rendered AF free
following successful ablation. Among the 37 patients who
remained with AF, one patient with a mechanical heart valve
had a thromboembolic event on warfarin despite a therapeutic
Table 2 Number of patients by CHADS2 and CHA2DS2-VASC scores











Fig. 1 Long-term AF-free rates by AF type (red=paroxysmal, blue=persistent, and green =longstanding persistent AF) for the initial ablation (left
panel) and after final ablation (right panel)
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INR. There were nine (8.3 %) instances of bleeding (rectal
bleeding in three, gastrointestinal bleeding in two, epistaxis in
two, bleeding skin graft in one, and leg hematoma after a fall
in one) among patients on OAC versus no bleeding events in
the group in whom OAC was discontinued (P=0.027). There
were three late deaths, two due to progressive congestive heart
failure in patients with preexisting cardiomyopathies and one
due to cancer.
4 Discussion
Our study has several important findings. First, there is a low
incidence of thromboembolic events in patients with a prior
history of CVA/TIA who undergo successful AF ablation.
Second, anticoagulation can be safely discontinued in the
majority of patients who appear AF free following ablation
with fewer bleeding complications in patients in whom OAC
is discontinued. Third, these patients should be left on
anticoagulation longer than the usual 3 months used for low-
risk patients following an ablation. Our data suggest that
patients with a prior CVA/TIA who undergo ablation should
be left on OAC for 1 year following a successful ablation to
minimize the risk associated with AF recurrence.
All of the major guidelines [1–3] currently recommend
continuing OAC in patients with significant risk factors for
thromboembolic events following ablation regardless of the
ablation outcome. These guideline recommendations are
made on a paucity of actual clinical data. Bunch et al. [4]
demonstrated that following AF ablation, patients have a
lower rate of subsequent stroke across all ranges of CHADS2
scores. They showed that the risk of subsequent stroke in
4,212 consecutive AF ablation patients was lower than a
matched control group of patients with AF who do not under-
go ablation and was similar to a matched group without AF.
What data are available (Table 3) suggest that it may be safe to
discontinue anticoagulation in high-risk patients, including
those with prior CVA/TIA, following an apparently successful
AF ablation. Oral et al. evaluated 755 patients undergoing an
AF ablation, 522 of whom were AF free following the abla-
tion [5]. Warfarin was discontinued in 79 % of 256 patients
without risk factors for thromboembolic events. It was also
discontinued in 68 % of 266 patients with one or more risk
factors for thromboembolic events. No patients in either group
had a thromboembolic event with an average of 25±
8.8 months of follow-up. In that study, 23/34 patients with a
prior history of CVA/TIA were AF free. Among those 23
patients, ten stopped OAC and 13 remained on OAC. All 11
patients who continued to have AF remained on OAC. None
of the 34 patients with a prior CVA/TIA had a thromboem-
bolic event during follow-up.
Themistoclakis et al. published the pooled outcomes from
five major ablation centers willing to stop OAC following
successful ablation despite the published guideline recom-
mendations [6]. They reported on 3,355 patients who were
AF free following ablation. OAC was discontinued in 2,692
(80.2 %) patients. There were 594 patients with CHADS2
score ≥2, and 347 (58.4 %) were off of OAC. There were
230 patients (6.9 %) with a prior history of CVA/TIA, and 125
of these (54.3 %) were off of anticoagulant therapy (Table 3).
None of the patients with a history of prior CVA/TIA (on or
off of OAC) experienced a thromboembolic event during
follow-up. The ischemic stroke risk for patients in whom
OAC was discontinued was 0.03 %/year, and it was 0.23 %/
year for those patients on OAC. The major bleeding rate was
0.98 %/year for those patients on OAC and 0.02 %/year for
those in whom it was discontinued (P <0.0001).
Saad et al. examined the long-term risk of thromboembolic
events off of OAC in 327 patients with a successful AF
catheter ablation [12]. The CHADS2 score was 2 or 3 in
68.8 %. Patients with higher CHADS2 scores had the time
of OAC discontinuation extended from 3 to 6–12 months
postablation. OACwas discontinued in 91% of these patients,
none of whom had a thromboembolic event during follow-up.
There were three (0.9 %) symptomatic hemorrhagic strokes
in patients receiving OAC. Chao et al. examined the long-
term adverse events (CVA, TIA, systemic embolism, pul-
monary embolism, or death) in 565 patients undergoing AF
ablation [13]. OAC was discontinued in some but not all
high-risk patients. They found an adverse event rate of
2.8 % among patients without AF versus 9.6 % in those
with AF recurrence (P =0.001). Although both the
CHADS2 and CHA2DS2-VASC scores predicted adverse
events, the authors did not examine outcomes separately
for the patients who were AF free compared to those who
continued to have AF.
Table 3 Summary of literature reports on stopping OAC in patients with prior CVA/TIA following a successful AF ablation
Total number of patients
AF free postablation
Number of AF-free





Oral et al. [5] 23 10 (43 %) 0 (0.0 %) 25±8.8
Themistoclakis et al. [6] 230 125 (54 %) 0 (0.0 %) 28±13
Present study 71 55 (77.5 %) 0 (0.0 %) 26±16
Total 324 190 (58.6 %) 0 (0.0 %)
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In our patient population, we discontinued OAC an average
of 7.3 months following their final ablation. Prior to stopping
OAC, we held discussions with the patients regarding the risks
and benefits of discontinuing OAC. They were advised that
many physicians would recommend continuing OAC. Al-
though we had no CVA/TIA in any patient in whom we
stopped OAC, the Kaplan–Meier curves in Fig. 1 suggest it
may have been prudent to continueOAC in these patients with
a prior CVA/TIAwho appear AF free postablation for 1 year
before discontinuing OAC. It is possible that we could have
safely stopped OAC in virtually all of our patients who
appeared AF free postablation; however, we tried to accom-
modate patients' and referring physicians' wishes in making a
decision to stop OAC.
Advocates of leaving patients at high risk for stroke on
OAC often point to the potential for silent AF burden which
could place the patient at risk for thromboembolic events.
Previous studies in our patients [14] and at a number of other
centers [15–18] suggest that the burden of only silent AF is
low in patients who are followed closely and remain clinically
AF free over the long term. The single study [19] demonstrat-
ing a high incidence of only asymptomatic AF following
ablation had a high percentage of patients on antiarrhythmic
drugs and 77 % on beta-blockers postablation, which may
have blunted patients' perceptions of recurrent AF. The
TRENDS study [20] examined AF burden in patients with
implanted devices in patients with and without a known
history of paroxysmal AF. When patients experienced an
episode of AF greater than 5.5 h in any 30-day period, they
had an increased risk of thromboembolic events. In a previous
study in our cohort of AF ablation, patients were evaluated an
average of 3 years postablation by 7-day monitoring and
implanted devices [14]. Only 1 of 203 patients had a single
episode of AF lasting longer than 5.5 h. The patients in the
TRENDS study did not undergo AF ablation and therefore
would be expected to have a higher risk of subsequent CVA/
TIA [4] than the patients in our series who did undergo AF
ablation. It is also likely that most of our highly symptomatic
patients would have noticed a 5.5-h episode of AF and noti-
fied us of their relapse.
Our long-term outcomes in these patients were reasonable
when examined by AF type (Fig. 1), but were slightly worse
when compared with our entire cohort of patients undergoing
AF ablation [7]. This lower AF-free rate may in part be due to
the high CHADS2 scores in the present study. Chao et al.
reported that for 247 patients with paroxysmal AF, the long-
term AF-free rate was 87% for those with a CHADS2 score of
0 and only 54.1 % for CHADS2 scores of ≥3 [21]. The
Kaplan–Meier curves in the present group of patients with
CVA/TIA appeared “flatter”with fewer late relapses than have
been reported in many other follow-up studies including our
own reports on our entire cohort of AF ablation patients [7]. It
is possible that the more intense early EKG monitoring in the
patients with previous CVA/TIA detected most of the ablation
failures earlier postablation which resulted in a lower early
success rate and a “flatter” late Kaplan–Meier curve.
4.1 Limitations
Our study is a single-center study with a relatively small
number of patients and a follow-up of only slightly more than
2 years. Despite being a high-volume AF ablation center, we
only had 108 patients undergoing ablation with prior CVA/
TIA. This suggests that cumulative data frommultiple centers,
such as shown in Table 3, will be required to definitively show
the safety of discontinuing OAC. Patients for whom antico-
agulation was discontinued were not randomized. However,
given the extremely low rate of CVA/TIA in these patients
postablation, it is unlikely enough patients could ever be
recruited into a randomized trial to show a reduction in events
by continuing OAC. The low rate of late recurrences in our
study may have also contributed to the lack of late thrombo-
embolic events after OACwas discontinued. It seems unlikely
that we had a high rate of silent AF in these patients. If that
were the case, one would have anticipated more thromboem-
bolic events when OAC was discontinued. All of our patients
were highly symptomatic before ablation and thus more likely
to be aware of clinical AF failures postablation and to notify
us immediately. Our findings should not be extrapolated to
less symptomatic or asymptomatic patients undergoing AF
ablation. All patients with risk factors for CVA/TIA need
lifelong follow-up after OAC is discontinued as they will
always be at risk for AF recurrence. All of our patients were
followed indefinitely by the ablating physicians, who contin-
ued to participate in anticoagulation decision making, in ad-
dition to their other physicians.
5 Conclusions
Patients with prior CVA/TIAs, who undergo successful AF
ablation, have a low incidence of subsequent thromboembolic
events. Most patients who appear AF free postablation may be
able to discontinue OAC after successful ablation with a low
thromboembolic risk and with a reduced bleeding risk. The
absence of thromboembolic events in our patients with prior
CVA/TIA and in other reported series of high-risk patients for
whom OAC has been discontinued following an apparently
successful AF ablation suggests that highly symptomatic pa-
tients, followed closely and indefinitely, may be able to safely
consider discontinuation of OAC. Our results suggest the need
for a multicenter randomized trial to definitively determine the
risk benefit of continuing or stopping OAC in these patients
after a successful AF ablation.
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